SLN124
Phase 2Small molecule
SLN124 is one of 9 small molecule programs targeting Polycythemia Vera. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Polycythemia Vera
#DrugCompanyPhaseTrials
1Droxia
TTheravia
Approved
BESREMI
PPharmaEssentia
Approved
Jakafi
IncytePhase 3
Trisenox
CCephalon
Approved
Ojjaara
GGlaxo Dba Glaxosmithkline
Approved
Zolinza
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Duvyzat
ItalfarmacoPhase 3
Mimrylo
TakedaPhase 3
SLN124
SSilence Therapeutics plc
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SLN124. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSilence Therapeutics plc